CompletedPhase 3

Rivaroxaban Anticoagulation for Superficial Vein Thrombosis

Canada85 participantsStarted 2014-11-11

Plain-language summary

This is a Phase III, randomized, placebo controlled, blinded, parallel two arm, multicentre trial that will compare rivaroxaban 10mg daily with placebo in patients with symptomatic leg Superficial Vein Thrombosis (\> or = 5cm) that otherwise would not initially be treated with anticoagulant therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Active bleeding
✕. Bleeding within the past 30 days due to a cause that has not fully resolved.
✕. Known or expected thrombocytopenia with a platelet count of less than 80,000 x 10 9/L.
✕. History of ever having had spontaneous intracranial bleeding, or any intracranial bleeding within the past 3 months.
✕. Receiving dual antiplatelet therapy (example. aspirin and clopidogrel).

What they're measuring

Efficacy

Timeframe: 90 days

Safety

Timeframe: 90 Days

Trial details

NCT IDNCT02123524

SponsorMcMaster University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-12-03

View on ClinicalTrials.gov More Symptomatic Superficial Vein Thrombosis trials